Ken-Ichi Oinuma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ken-Ichi Oinuma has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
Arata Sakiyama
6 shared publicationsYukihiro Kaneko
Department of Bacteriology, Osaka Metropolitan University Graduate School of Medicine
6 shared publications- Taishi Tsubouchi
Department of Bacteriology, Graduate School of Medicine, Osaka City University, Abeno, Osaka, Japan
4 shared publications Chaogetu Saren
3 shared publicationsMamiko Niki
Department of Bacteriology, Osaka Metropolitan University Graduate School of Medicine
3 shared publications- Masato Suzuki
Antimicrobial Resistance Research Center, National Institute of Infectious Diseases
3 shared publications
Latest Publications
- Open Access
- 11 February 2026
- Published by American Society for Microbiology in mBio
- Vol. 17 (2) , e0236625
Benefits and costs of a hypercapsule and the mechanism of its loss in a clinical isolate of Acinetobacter baumannii
Acinetobacter baumannii is an opportunistic pathogen in which capsule production is closely linked to immune evasion and environmental persistence. Recent studies have described two seemingly contradictory phenomena—increasing prevalence of capsule-overproducing clinical isolates and frequent isolation of capsule-deficient variants. The biological significance of these phenomena remains unclear. In this study, we analyzed a clinical isolate, OCU_Ac16b, which spontaneously gives rise to two phenotypically distinct variants: the L type forming large colonies with a prominent hypercapsule (>1 µm thick), and the S type forming small colonies with a substantially reduced or absent capsule. When L-type cells were cultured in test tubes under low-shaking conditions, S-type variants reproducibly emerged, constituting approximately 40%–80% of the population within 24 h. Whole-genome sequencing revealed that this conversion is driven by distinct mutations in the capsular polysaccharide synthesis cluster, including insertion sequence insertions and a single-nucleotide deletion. Dilution experiments demonstrated that L-to-S conversion mutations arise de novo during liquid culture at sufficiently high rates to account for the rapid and reproducible emergence of S-type variants. Phenotypic characterization demonstrated a biological trade-off, with L-type cells exhibiting enhanced resistance to serum killing, desiccation, and certain β-lactam antibiotics, whereas S-type cells showed superior surface attachment, increased biofilm formation, and a growth advantage under oxygen-limited conditions. Our findings uncover a highly reproducible, mutation-driven capsule switching mechanism that enables rapid phenotypic adaptation to changing environments. This phenotypic heterogeneity has significant implications for pathogenesis, persistence, diagnostic evaluation, and clinical management. IMPORTANCE: Acinetobacter baumannii is a clinically important opportunistic pathogen that exhibits striking phenotypic diversity. In particular, some clinical isolates produce unusually thick capsules, which are thought to contribute to immune evasion and persistence, while others lack the capsule altogether. However, the biological significance of these contrasting phenotypes has remained unclear. We analyzed a clinical isolate that spontaneously gives rise to capsule-deficient variants from a hypercapsulated form. We found that the conversion is driven by spontaneous mutations in capsule biosynthesis genes, including de novo mutations arising during liquid culture, while the expansion of capsule-deficient cells is promoted under oxygen-limited conditions. The two variants differed in serum resistance, desiccation tolerance, growth characteristics, and antibiotic responses, revealing a trade-off between protective barriers and environmental adaptability. These findings provide new insights into how A. baumannii may balance survival strategies through genetic and phenotypic heterogeneity, with potential implications for diagnosis, treatment, and bacterial persistence in clinical settings.
- 11 February 2026
- Published by American Society for Microbiology in mBio
- Vol. 17 (2) , e0236625
Open AccessBenefits and costs of a hypercapsule and the mechanism of its loss in a clinical isolate of Acinetobacter baumannii
Acinetobacter baumannii is an opportunistic pathogen in which capsule production is closely linked to immune evasion and environmental persistence. Recent studies have described two seemingly contradictory phenomena—increasing prevalence of capsule-overproducing clinical isolates and frequent isolation of capsule-deficient variants. The biological significance of these phenomena remains unclear. In this study, we analyzed a clinical isolate, OCU_Ac16b, which spontaneously gives rise to two phenotypically distinct variants: the L type forming large colonies with a prominent hypercapsule (>1 µm thick), and the S type forming small colonies with a substantially reduced or absent capsule. When L-type cells were cultured in test tubes under low-shaking conditions, S-type variants reproducibly emerged, constituting approximately 40%–80% of the population within 24 h. Whole-genome sequencing revealed that this conversion is driven by distinct mutations in the capsular polysaccharide synthesis cluster, including insertion sequence insertions and a single-nucleotide deletion. Dilution experiments demonstrated that L-to-S conversion mutations arise de novo during liquid culture at sufficiently high rates to account for the rapid and reproducible emergence of S-type variants. Phenotypic characterization demonstrated a biological trade-off, with L-type cells exhibiting enhanced resistance to serum killing, desiccation, and certain β-lactam antibiotics, whereas S-type cells showed superior surface attachment, increased biofilm formation, and a growth advantage under oxygen-limited conditions. Our findings uncover a highly reproducible, mutation-driven capsule switching mechanism that enables rapid phenotypic adaptation to changing environments. This phenotypic heterogeneity has significant implications for pathogenesis, persistence, diagnostic evaluation, and clinical management. IMPORTANCE: Acinetobacter baumannii is a clinically important opportunistic pathogen that exhibits striking phenotypic diversity. In particular, some clinical isolates produce unusually thick capsules, which are thought to contribute to immune evasion and persistence, while others lack the capsule altogether. However, the biological significance of these contrasting phenotypes has remained unclear. We analyzed a clinical isolate that spontaneously gives rise to capsule-deficient variants from a hypercapsulated form. We found that the conversion is driven by spontaneous mutations in capsule biosynthesis genes, including de novo mutations arising during liquid culture, while the expansion of capsule-deficient cells is promoted under oxygen-limited conditions. The two variants differed in serum resistance, desiccation tolerance, growth characteristics, and antibiotic responses, revealing a trade-off between protective barriers and environmental adaptability. These findings provide new insights into how A. baumannii may balance survival strategies through genetic and phenotypic heterogeneity, with potential implications for diagnosis, treatment, and bacterial persistence in clinical settings.
- Open Access
Benefits and costs of a hypercapsule and the mechanism of its loss in a clinical isolate of Acinetobacter baumannii
Acinetobacter baumannii is an opportunistic pathogen in which capsule production is closely linked to immune evasion and environmental persistence. Recent studies have described two seemingly contradictory phenomena—increasing prevalence of capsule-overproducing clinical isolates and frequent isolation of capsule-deficient variants. The biological significance of these phenomena remains unclear. In this study, we analyzed a clinical isolate, OCU_Ac16b, which spontaneously gives rise to two phenotypically distinct variants: the L type forming large colonies with an extremely thick capsule, and the S type forming small colonies with a substantially reduced or absent capsule. When L-type cells were cultured in test tubes under low-shaking conditions, S-type variants reproducibly emerged, constituting 45–80% of the population within 24 hours. Whole-genome sequencing revealed that this conversion is driven by distinct mutations in the capsular polysaccharide synthesis cluster, including insertion sequence (IS) insertions and a single-nucleotide deletion. PCR analysis confirmed that IS insertions in wzy (polysaccharide polymerase) occur within individual L-type colonies prior to liquid culture, providing a likely explanation for the rapid and reproducible emergence of S-type variants. Phenotypic characterization demonstrated a biological trade-off, with L-type cells exhibiting enhanced resistance to serum killing, desiccation, and certain β-lactam antibiotics, whereas S-type cells showed superior surface attachment, increased biofilm formation, and a growth advantage under oxygen-limited conditions. Our findings uncover a highly reproducible, mutation-driven capsule switching mechanism that enables rapid phenotypic adaptation to changing environments. This phenotypic heterogeneity has significant implications for pathogenesis, persistence, diagnostic evaluation, and clinical management. Importance: Acinetobacter baumannii is a clinically important opportunistic pathogen that exhibits striking phenotypic diversity. In particular, some clinical isolates produce unusually thick capsules, which are thought to contribute to immune evasion and persistence, while others lack capsule altogether. However, the biological significance of these contrasting phenotypes has remained unclear. In this study, we analyzed a clinical isolate that spontaneously gives rise to capsule-deficient variants from a hypercapsulated form. We found that the conversion is driven by spontaneous mutations in capsule biosynthesis genes that arise naturally within colonies, while the expansion of capsule-deficient cells is promoted under oxygen-limited conditions. The two variants differed in serum resistance, desiccation tolerance, growth characteristics, and antibiotic responses, revealing a trade-off between protective barriers and environmental adaptability. These findings provide new insights into how A. baumannii balances survival strategies through genetic and phenotypic heterogeneity, with important implications for diagnosis, treatment, and bacterial persistence in clinical settings.
Open AccessBenefits and costs of a hypercapsule and the mechanism of its loss in a clinical isolate of Acinetobacter baumannii
Acinetobacter baumannii is an opportunistic pathogen in which capsule production is closely linked to immune evasion and environmental persistence. Recent studies have described two seemingly contradictory phenomena—increasing prevalence of capsule-overproducing clinical isolates and frequent isolation of capsule-deficient variants. The biological significance of these phenomena remains unclear. In this study, we analyzed a clinical isolate, OCU_Ac16b, which spontaneously gives rise to two phenotypically distinct variants: the L type forming large colonies with an extremely thick capsule, and the S type forming small colonies with a substantially reduced or absent capsule. When L-type cells were cultured in test tubes under low-shaking conditions, S-type variants reproducibly emerged, constituting 45–80% of the population within 24 hours. Whole-genome sequencing revealed that this conversion is driven by distinct mutations in the capsular polysaccharide synthesis cluster, including insertion sequence (IS) insertions and a single-nucleotide deletion. PCR analysis confirmed that IS insertions in wzy (polysaccharide polymerase) occur within individual L-type colonies prior to liquid culture, providing a likely explanation for the rapid and reproducible emergence of S-type variants. Phenotypic characterization demonstrated a biological trade-off, with L-type cells exhibiting enhanced resistance to serum killing, desiccation, and certain β-lactam antibiotics, whereas S-type cells showed superior surface attachment, increased biofilm formation, and a growth advantage under oxygen-limited conditions. Our findings uncover a highly reproducible, mutation-driven capsule switching mechanism that enables rapid phenotypic adaptation to changing environments. This phenotypic heterogeneity has significant implications for pathogenesis, persistence, diagnostic evaluation, and clinical management. Importance: Acinetobacter baumannii is a clinically important opportunistic pathogen that exhibits striking phenotypic diversity. In particular, some clinical isolates produce unusually thick capsules, which are thought to contribute to immune evasion and persistence, while others lack capsule altogether. However, the biological significance of these contrasting phenotypes has remained unclear. In this study, we analyzed a clinical isolate that spontaneously gives rise to capsule-deficient variants from a hypercapsulated form. We found that the conversion is driven by spontaneous mutations in capsule biosynthesis genes that arise naturally within colonies, while the expansion of capsule-deficient cells is promoted under oxygen-limited conditions. The two variants differed in serum resistance, desiccation tolerance, growth characteristics, and antibiotic responses, revealing a trade-off between protective barriers and environmental adaptability. These findings provide new insights into how A. baumannii balances survival strategies through genetic and phenotypic heterogeneity, with important implications for diagnosis, treatment, and bacterial persistence in clinical settings.
- Open Access
- 20 May 2023
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-14
Identification of a mycobacterial hydrazidase, an isoniazid-hydrolyzing enzyme
There exists decades-old evidence that some mycobacteria, including Mycobacterium avium and Mycobacterium smegmatis, produce hydrazidase, an enzyme that can hydrolyze the first-line antitubercular agent isoniazid. Despite its importance as a potential resistance factor, no studies have attempted to reveal its identity. In this study, we aimed to isolate and identify M. smegmatis hydrazidase, characterize it, and evaluate its impact on isoniazid resistance. We determined the optimal condition under which M. smegmatis produced the highest amount of hydrazidase, purified the enzyme by column chromatography, and identified it by peptide mass fingerprinting. It was revealed to be PzaA, an enzyme known as pyrazinamidase/nicotinamidase whose physiological role remains unknown. The kinetic constants suggested that this amidase with broad substrate specificity prefers amides to hydrazides as a substrate. Notably, of the five tested compounds, including amides, only isoniazid served as an efficient inducer of pzaA transcription, as revealed by quantitative reverse transcription PCR. Moreover, high expression of PzaA was confirmed to be beneficial for the survival and growth of M. smegmatis in the presence of isoniazid. Thus, our findings suggest a possible role for PzaA, and other hydrazidases yet to be identified, as an intrinsic isoniazid resistance factor of mycobacteria.
- 20 May 2023
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-14
Open AccessIdentification of a mycobacterial hydrazidase, an isoniazid-hydrolyzing enzyme
There exists decades-old evidence that some mycobacteria, including Mycobacterium avium and Mycobacterium smegmatis, produce hydrazidase, an enzyme that can hydrolyze the first-line antitubercular agent isoniazid. Despite its importance as a potential resistance factor, no studies have attempted to reveal its identity. In this study, we aimed to isolate and identify M. smegmatis hydrazidase, characterize it, and evaluate its impact on isoniazid resistance. We determined the optimal condition under which M. smegmatis produced the highest amount of hydrazidase, purified the enzyme by column chromatography, and identified it by peptide mass fingerprinting. It was revealed to be PzaA, an enzyme known as pyrazinamidase/nicotinamidase whose physiological role remains unknown. The kinetic constants suggested that this amidase with broad substrate specificity prefers amides to hydrazides as a substrate. Notably, of the five tested compounds, including amides, only isoniazid served as an efficient inducer of pzaA transcription, as revealed by quantitative reverse transcription PCR. Moreover, high expression of PzaA was confirmed to be beneficial for the survival and growth of M. smegmatis in the presence of isoniazid. Thus, our findings suggest a possible role for PzaA, and other hydrazidases yet to be identified, as an intrinsic isoniazid resistance factor of mycobacteria.
- 1 April 2023
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 61 (5) , 106767
Differences in severity of bacteraemia caused by hypermucoviscous and non-hypermucoviscous Klebsiella pneumoniae
- 1 April 2023
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 61 (5) , 106767
Differences in severity of bacteraemia caused by hypermucoviscous and non-hypermucoviscous Klebsiella pneumoniae
- Open Access
- 23 December 2022
- Published by Elsevier in Journal of Global Antimicrobial Resistance
- Vol. 32, 21-28
Rifampicin exerts anti-mucoviscous activity against hypervirulent Klebsiella pneumoniae via binding to the RNA polymerase β subunit
- 23 December 2022
- Published by Elsevier in Journal of Global Antimicrobial Resistance
- Vol. 32, 21-28
Open AccessRifampicin exerts anti-mucoviscous activity against hypervirulent Klebsiella pneumoniae via binding to the RNA polymerase β subunit
- 21 December 2022
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 29 (3) , 322-328
Discovery of a LuxR-type regulator involved in isoniazid-dependent gene regulation in Mycobacterium smegmatis
- 21 December 2022
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 29 (3) , 322-328
Discovery of a LuxR-type regulator involved in isoniazid-dependent gene regulation in Mycobacterium smegmatis
- Open Access
- 27 September 2022
- Published by Springer Nature in Research Square
Identification of a mycobacterial hydrazidase, an isoniazid-hydrolyzing enzyme
There is decades-old evidence that some mycobacteria, including Mycobacterium avium and Mycobacterium smegmatis, produce hydrazidase, an enzyme that can hydrolyze the first-line anti-tubercular agent isoniazid. Despite its importance as a potential resistance factor, no studies have attempted to reveal its identity. In this study, we aimed to isolate and identify M. smegmatis hydrazidase, characterize it, and evaluate its impact on isoniazid resistance. We determined the optimal condition under which M. smegmatis produced the highest amount of hydrazidase, purified the enzyme by column chromatography, and identified it by peptide mass fingerprinting. It was revealed to be PzaA, an enzyme known as pyrazinamidase/nicotinamidase whose physiological role remains unknown. The kinetic constants suggested that this amidase with broad substrate specificity prefers amides to hydrazides as a substrate. Interestingly, however, of the five tested compounds, including amides, only isoniazid served as an efficient inducer of pzaA transcription, as revealed by quantitative reverse transcription PCR. Moreover, high expression of PzaA was confirmed to be beneficial for the survival of M. smegmatis in the presence of isoniazid. Our findings suggest a possible role for PzaA and other hydrazidases yet to be identified as an intrinsic isoniazid resistance factor of mycobacteria.
- 27 September 2022
- Published by Springer Nature in Research Square
Open AccessIdentification of a mycobacterial hydrazidase, an isoniazid-hydrolyzing enzyme
There is decades-old evidence that some mycobacteria, including Mycobacterium avium and Mycobacterium smegmatis, produce hydrazidase, an enzyme that can hydrolyze the first-line anti-tubercular agent isoniazid. Despite its importance as a potential resistance factor, no studies have attempted to reveal its identity. In this study, we aimed to isolate and identify M. smegmatis hydrazidase, characterize it, and evaluate its impact on isoniazid resistance. We determined the optimal condition under which M. smegmatis produced the highest amount of hydrazidase, purified the enzyme by column chromatography, and identified it by peptide mass fingerprinting. It was revealed to be PzaA, an enzyme known as pyrazinamidase/nicotinamidase whose physiological role remains unknown. The kinetic constants suggested that this amidase with broad substrate specificity prefers amides to hydrazides as a substrate. Interestingly, however, of the five tested compounds, including amides, only isoniazid served as an efficient inducer of pzaA transcription, as revealed by quantitative reverse transcription PCR. Moreover, high expression of PzaA was confirmed to be beneficial for the survival of M. smegmatis in the presence of isoniazid. Our findings suggest a possible role for PzaA and other hydrazidases yet to be identified as an intrinsic isoniazid resistance factor of mycobacteria.
- Open Access
- 30 September 2021
- Published by American Society for Microbiology in Microbiology Resource Announcements
- Vol. 10 (39) , e0069521
Complete Genome Sequence of a Clinical Isolate of Acinetobacter baumannii Harboring 11 Plasmids
Here, we report the complete genome sequence of an Acinetobacter baumannii isolate harboring 11 plasmids, obtained at a hospital in Japan in 2016. The complete 4.07-Mbp genome sequence (1 chromosome and 11 plasmids) was analyzed by a combination of long-read (Flongle) and short-read (NovaSeq 6000) sequencing.
- 30 September 2021
- Published by American Society for Microbiology in Microbiology Resource Announcements
- Vol. 10 (39) , e0069521
Open AccessComplete Genome Sequence of a Clinical Isolate of Acinetobacter baumannii Harboring 11 Plasmids
Here, we report the complete genome sequence of an Acinetobacter baumannii isolate harboring 11 plasmids, obtained at a hospital in Japan in 2016. The complete 4.07-Mbp genome sequence (1 chromosome and 11 plasmids) was analyzed by a combination of long-read (Flongle) and short-read (NovaSeq 6000) sequencing.
- Open Access
- 1 September 2018
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 503 (3) , 1581-1586
Extracytoplasmic diaphorase activity of Streptomyces coelicolor A3(2)
- 1 September 2018
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 503 (3) , 1581-1586
Open AccessExtracytoplasmic diaphorase activity of Streptomyces coelicolor A3(2)
- Open Access
- 1 January 2018
- Published by CLOCKSS Archive in HETEROCYCLES
- Vol. 96 (6) , 1075-1079
Novel Antioxidant Isolated from Warcupiella spinulosa JCM 2358, 7-Hydroxycordylactam
- 1 January 2018
- Published by CLOCKSS Archive in HETEROCYCLES
- Vol. 96 (6) , 1075-1079
Open AccessNovel Antioxidant Isolated from Warcupiella spinulosa JCM 2358, 7-Hydroxycordylactam